Neuphoria Therapeutics Net Income Over Time
| NEUP Stock | 4.05 0.02 0.49% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Neuphoria Therapeutics Performance and Neuphoria Therapeutics Correlation. Neuphoria | Build AI portfolio with Neuphoria Stock |
Can Biotechnology industry sustain growth momentum? Does Neuphoria have expansion opportunities? Factors like these will boost the valuation of Neuphoria Therapeutics. Anticipated expansion of Neuphoria directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Neuphoria Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Neuphoria Therapeutics's market price often diverges from its book value, the accounting figure shown on Neuphoria's balance sheet. Smart investors calculate Neuphoria Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Neuphoria Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Neuphoria Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuphoria Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Neuphoria Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Neuphoria Therapeutics and related stocks such as Pheton Holdings, Inspira Technologies Oxy, and Biomerica Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IINN | (39.6 K) | (39.6 K) | (39.6 K) | (39.6 K) | (39.6 K) | (39.6 K) | (39.6 K) | (39.6 K) | (39.6 K) | (4.6 M) | (7.2 M) | (17 M) | (4 M) | (11.3 M) | (11.1 K) | (9.9 K) | (10.4 K) |
| BMRA | (1.9 M) | 548.4 K | 537 K | (215.7 K) | (331.4 K) | (1.5 M) | (908.6 K) | (1.5 M) | (2.4 M) | (2.3 M) | (7.4 M) | (4.5 M) | (7.1 M) | (6 M) | (5 M) | (4.5 M) | (4.3 M) |
| PFSA | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (20.2 M) | (10.3 M) | (9.2 M) | (10.6 M) | (11.1 M) |
| APRE | (3.5 M) | (254 K) | (254 K) | (436.2 K) | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (15.5 M) | (28.1 M) | (53.9 M) | (36.5 M) | (112.7 M) | (14.3 M) | (13 M) | (11.7 M) | (12.2 M) |
| LUCY | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (768.2 K) | (3.2 M) | (5.7 M) | (6.7 M) | (7.8 M) | (7 M) | (6.6 M) |
| BCDA | 135.6 K | 9.7 M | 305 K | 19 K | 234 K | 322 K | (10.3 M) | (12.3 M) | (14 M) | (14.7 M) | (15 M) | (12.6 M) | (11.9 M) | (11.6 M) | (7.9 M) | (7.2 M) | (6.8 M) |
| ALZN | (69.5 K) | (69.5 K) | (69.5 K) | (69.5 K) | (69.5 K) | (69.5 K) | (1.6 M) | (932 K) | (4.9 M) | (4.4 M) | (5 M) | (12.4 M) | (14.9 M) | (9.9 M) | (4.5 M) | (4.1 M) | (4.3 M) |
| LFWD | (32.5 M) | (32.5 M) | (32.5 M) | (32.5 M) | (32.5 M) | (32.5 M) | (32.5 M) | (24.7 M) | (21.7 M) | (15.6 M) | (13 M) | (12.7 M) | (19.6 M) | (22.1 M) | (28.9 M) | (33.3 M) | (34.9 M) |
Neuphoria Therapeutics and related stocks such as Pheton Holdings, Inspira Technologies Oxy, and Biomerica Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Neuphoria Therapeutics financial statement analysis. It represents the amount of money remaining after all of Neuphoria Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Neuphoria Therapeutics | NEUP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 100 Summit Drive, |
| Exchange | NASDAQ Exchange |
null 4.05
Additional Tools for Neuphoria Stock Analysis
When running Neuphoria Therapeutics' price analysis, check to measure Neuphoria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuphoria Therapeutics is operating at the current time. Most of Neuphoria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Neuphoria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuphoria Therapeutics' price. Additionally, you may evaluate how the addition of Neuphoria Therapeutics to your portfolios can decrease your overall portfolio volatility.